Resources and information for parents of children with cancer . . . by parents of children with cancer.

Bibliography

(as referenced in the MRD pages on this site)

(1) Molecular Diagnostics for the Clinical Laboratorian. Edited by Wiliam B. Coleman and Gregory J. Tsongalis. Humana Press, Totowa NJ, 1997.

(2) Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416-34.

(3) Pui C-H. Childhood leukemias. N Engl J Med 1995; 332: 1618-30.

(4) Laszlo, J. The Cure of Childhood Leukemia. Rutgers University Press, 1996.

(5) Morley, Alec. Quantifying Leukemia. (Editorial) NEJM 339; 9.

(6) Van Dongen, JJM, Seriu, E, Biondi, A, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: number 9142.

(7) Foon, KA, and Todd, RF. Immunologic classification of leukemia and lymphoma. Blood 68:1-31, 1986.

(8) Negrin, RS and Blume, KG. The use of polymerase chain reaction for the detection of minimal residual malignant disease. Blood 78; 255-8, 1991.

(9) Sklar, J. Polymerase chain reaction: the molecular microscope of residual disease. Blood 78; 255-8, 1991.

(10) Van Dongen JJM, Breit TM, Adriaansen HJ, Beishizen A, Hooijkaas H. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992; 6S1: 47-59.

(11) Bartram CR. Detection of minimal residual leukemia by the polymerase chain reaction; potential implications for therapy. Clin Chim Acta 1993; 217: 75-83.

(12) Van Dongen JJM, Szczep’nski T, de Bruijn MAC, et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther 1996; 2: 121-33.

(13) Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550-4.

(14) Farahat N, Morilla A, Owusu-Ankomah K, et al. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry. Br J Haematol 1998; 101: 158-64.

(15) Anastasi, J, Vardima, JW, Rudinsky, R, Patel M, Nachman J, Rubin CM, and Le Beau MM. Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia. Blood 77: 2456-62, 1991.

(16) Zhao, L, Chang K-S, Hayes, K, Deisseroth, AB, and Liang, JC. Detection of residual leukemic cells in patients with acute promyelocytic leukemia by the fluorescence in situ hybridization method: potential for predicting relapse. Blood 85; 495-9, 1995.

(17) Zhao, L, Kantarjian, HM, Van, OJ, Cork, A, Truillo, JM, and Liang, JC. Detection of residual proliferating leukemia cells by fluorescence in situ hybridization in CML patients in complete remission after interferon therapy. Leukemia 7: 168-71, 1993.

(18) Heerema, NA, Argyropoulos, G, Weetman, R, Tricot, G, and Secker-Walker, LM. Interphase in situ hybridization reveals minimal residual disease in early remission and return of the diagnostic clone in karyotypically normal relapse of acute lymphoblastic leukemia. Leukemia 7: 537-43m 1993.

(19) Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med 1998 Aug 27;339(9):591-8.

(20) Cave H, Guidal C, Rohrlich P, et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of gamma and delta T-cell receptor genes. Blood 1994; 83: 1892-902.

(21) Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClian KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. NEJM 1997; 336: 317-23.

(22) Ouspenskaia MV, Johnston DA, Roberts WM, Estrov Z, Zipf TF. Accurate quantitation o residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia 1995; 9: 321-8

(23) Heerema, NA, Argyropoulos, G, Weetman, R, Tricot, G, and SEcker-Walker, LM. Interphase in situ hybridization reveals minimal residual disease in early remission and return of the diagnostic clone in karyotypically normal relapse of acute lymphoblastic leukemia. Leukemia 7: 537-43m 1993.

(24) Anastasi, J, Vardima, JW, Rudinsky, R, Patel M, Nachman J, Rubin CM, and Le Beau MM. Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia. Blood 77: 2456-62, 1991.

(25) Kasprzyk A, Secker-Walker LM. Increased sensitivity of minimal residual disease detection by interphase FISH in acute lymphoblastic leukemia with hyperdiploidy. Leukemia 1997 Mar;11(3):429-35.

(26) Gale RP, Butturini A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. Lancet 1991;338: 1315-8.

General Disclaimer

These pages are intended for informational purposes only and are not intended to render medical advice. The information provided on Ped Onc Resource Center should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you suspect your child has a health problem, you should consult your health care provider.

contact webmaster/ped-onc home/last updated 7/05